Digging into the SECURE T2D publication data: diverse patients, powerful outcomes

The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

In this episode, we dive into the SECURE T2D publication, with Dr. Chris Bajaj, an author and investigator in this groundbreaking study. Featuring a diverse population of participants with type 2 diabetes, the study revealed significant A1C reduction1, especially for those participants with baseline A1C above 9%. We also explore the simplified bolus strategies used to support patients, including those not carb counting at the start of the study. Tune in to learn how this research is shaping real-world diabetes care for people living with type 2 diabetes!

1. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. In a subgroup analysis of 68 participants with baseline A1c ≥ 9% Mean HbA1c: ST vs. 13-week Omnipod 5: 10.1% vs. 8.1%; (95% CI: -2.3%, -1.9%)